Information sur le laboratoire
Jean-Pierre Routy (M.D.)
Scientifique séniorCentre de biologie translationnelle
Département de médecine (McGill)
Profil de recherche
Mots-clés
VIH • Infections virales chroniques • CMV • HHV8 • Réservoirs du VIH • IntestinIntérêts de recherche
Mes recherches portent sur la pathogenèse du virus de l'immunodéficience humaine (VIH), dans le but de trouver un traitement contre cette maladie. L'amélioration des connaissances sur la tolérance immunitaire dans le cancer et l'immunométabolisme sera essentielle à l'élaboration d'une stratégie visant à vaincre les cancers et les maladies auto-immunes.Membre de l'équipe
| Nom | Poste |
|---|
Dernières publications
- Al-Abdulmalek, A., Isnard, S., Watters, A. A. & Routy, J.-P. (2026). From suspected brain malignancy to Erdheim-Chester disease: the role of PET imaging and bone marrow biopsy in diagnosis. Oxford medical case reports, vol. 2026, p. omag049.
- Meissner, E. G., Ramgopal, M., Ruane, P. J., Sanchez, W., Crofoot, G., Routy, J.-P., Brinson, C., DeJesus, E., Martorell, C. T., Tellez, M., Yokomaku, Y., O'Reilly, M., Lupo, S., Schellberg, S., Lezama-Mora, J. I., Chin, B., Aizen, K., D'Antoni, M. L., Huang, H., Mponponsuo, K., Montezuma-Rusca, J. M., Sklar, P., Rhee, M., Hung, C.-C. & ARTISTRY-2 Study Group (2026). Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. The lancet. HIV.
- Fava, V. M., Dallmann-Sauer, M., Orlova, M., Correa-Macedo, W., Olivenstein, R., Costiniuk, C. T., Routy, J.-P., Barreiro, L. B. & Schurr, E. (2026). Continuous antiretroviral therapy induces progressive senescence-like reprogramming of alveolar macrophages. Frontiers in immunology, vol. 17, p. 1805936.
- Al-Abdulmalek, A., Landry, E., Abdulgayoom, M., Al-Mashdali, A. F., Dalol, A. A., Muthanna, B., Routy, J.-P. & Mohamed, S. F. (2026). BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance. Current hematologic malignancy reports, vol. 21.
- Luo, Y. H., Zuberi, N., Rizzolo, A., Warner, M., Isnard, S. & Routy, J.-P. (2026). Stroke From Paradoxical Embolism in a Young Patient With Sickle-Cell Disease and High Fetal Hemoglobin: A Diagnostic Challenge. Clinical case reports, vol. 14, p. e72618.
- Sun, L., Jiang, Y., Isnard, S., Chen, J., Li, Y., Wang, H., Zhao, F., Rao, M., Jia, X., Huang, J., Wu, J., Luo, Y., Zhao, D., Liu, C., Li, X., Routy, J.-P., Liu, J., He, Y., Cen, P. & Lu, H. (2026). Comparative safety and efficacy of BIC/FTC/TAF versus DTG+3TC in antiretroviral treatment-naive patients with HIV as first-line regimens: A real-world cohort study. Bioscience trends, vol. 20, p. 205-216.
- Isnard, S., Royston, L., Berini, C. A., Mabanga, T., Al-Abdulmalek, A., Aiyana, O., Sun, L., El-Far, M., Pagliuzza, A., Planas, D., Bu, S., Pardesi, M. K., Fromentin, R., Ancuta, P., Durand, M., Chomont, N. & Routy, J.-P. (2026). Plasma GDF-15 levels are associated with HIV reservoir markers independently of inflammation in people with HIV on antiretroviral therapy. The Journal of infectious diseases.
- Roussel, L., Bernier, S., Langelier, M., Sun, Y., Mak, B., Li, Y., Perez, A., Wloski, A., Angers, I., Vinh, L.-R., Beauchamp, A., Boissel, S., Watters, A. K., Rousseau, S., Routy, J.-P., Calderon, V., Arias, C. & Vinh, D. C. (2026). Human retinoic acid-inducible gene I (RIG-I) deficiency associated with susceptibility to classic Kaposi sarcoma. The Journal of allergy and clinical immunology.
- Routy, J.-P. & Isnard, S. (2026). Increasing handgrip strength to combat frailty in HIV: Linking immune exhaustion to a bone health indicator. The Journal of infectious diseases.
- Isnard, S., Berini, C. A., Parvathy, S. N., Feng, H., Aiyana, O., Royston, L., Mabanga, T., Lakatos, P. L., Bessissow, T., Klein, M. B., Lebouché, B., Costiniuk, C. T., Routy, B., Silverman, M. S. & Routy, J.-P. (2025). Fecal microbiota transplantation to reduce immune activation in ART-treated people with HIV with low CD4/CD8 ratio: protocol for the single-blind, randomized, placebo-controlled Gutsy study (CIHR/CTN PT038). Trials, vol. 27, p. 52.
Voir aussi
